The Pharmacy Down the Block Could Save Your Life. Congress Has Been Keeping It Out of Reach.

On a Tuesday morning in March 2026, a 38-year-old woman named Dana — who asked that only her first name be used — drove 94 miles round-trip to the methadone clinic in Tucson where she had been receiving treatment for opioid use disorder for three years. She left her house at 5:45 a.m. to make it before her shift at the warehouse started at 8:30. She was not sick. She was not in crisis. Her dose had been stable for eighteen months. She just had to go, because the law said she had to go, because in the United States in 2026, methadone — the most effective medication for opioid use disorder ever studied — still cannot be called in to a pharmacy.

“There is a Walgreens four blocks from my house,” Dana said. “My blood pressure medication is there. My thyroid medication is there. The medication that keeps me alive is in another county.”

On Thursday, June 25, 2026, two U.S. senators introduced legislation that would change that. The bill — a reintroduction of the Modernizing Opioid Treatment Access Act, first introduced in 2023 — would allow board-certified addiction medicine and addiction psychiatry physicians to prescribe methadone for opioid use disorder directly, with patients able to fill the prescription at any licensed pharmacy. The current requirement, that patients can only receive methadone through roughly 2,000 specially licensed Opioid Treatment Programs, would remain but would no longer be the only legal option.

“For too long, we have kept methadone — an evidence-based, life-saving medication — locked away from the people who need it most,” said Sen. Ed Markey (D-Mass.), the bill’s lead sponsor. “This legislation removes an arbitrary barrier to treatment and trusts doctors to do their jobs.”

The bill is straightforward. The barrier it’s fighting is not.

The Law That Froze in 1974

Methadone has been used to treat opioid dependence since the 1960s, when Drs. Vincent Dole and Marie Nyswander at Rockefeller University published their seminal work showing it dramatically reduced heroin use, criminal activity, and mortality among patients. By 1971, federal programs were funding methadone maintenance treatment. By 1974, Congress had passed the Narcotic Addict Treatment Act — the law that restricted methadone dispensing for addiction treatment to specially licensed clinics, separated entirely from the medical mainstream.

The rationale at the time was partly public health — concerns about diversion — and partly something less clinical. Heroin addiction in 1974 was, in the public imagination and in political rhetoric, a moral failure of specific communities: Black and Latino urban neighborhoods, Vietnam veterans, the “junkie” archetype that Richard Nixon’s drug war was explicitly designed to stigmatize and contain. Methadone clinics were not built into the fabric of American medicine. They were built into specific neighborhoods, regulated at arm’s length from doctors’ offices and pharmacies, constructed as a kind of controlled quarantine.

That architecture has not fundamentally changed in 52 years.

What has changed is everything around it. In 2000, Congress passed the Drug Addiction Treatment Act, which allowed physicians with a waiver to prescribe buprenorphine — a partial opioid agonist that is less effective than methadone for many patients, particularly those with severe dependence — from their offices. In December 2022, Congress eliminated the waiver requirement entirely: any provider with a standard DEA registration can now prescribe buprenorphine. The barrier for buprenorphine essentially vanished.

The barrier for methadone did not move.

The result is a two-tier system that allocates treatment by geography, transportation, employment flexibility, and — as decades of research have documented — race. Opioid Treatment Program clinics are concentrated in urban areas. Methadone patients must typically attend the clinic daily for the first phase of treatment, then weekly, then monthly if they demonstrate stability. In rural counties, in states like Arizona where public transit is sparse, in zip codes where a 90-minute round-trip represents an insurmountable obstacle, this daily requirement is not just inconvenient. It is an effective denial of care.

The result is a two-tier system that allocates treatment by geography, transportation, employment flexibility, and — as decades of research have documented — race.

Methadone Works. That’s the Uncomfortable Part.

The clinical evidence for methadone is not ambiguous. It is not “promising” or “shows potential.” It is as settled as medical evidence gets in addiction treatment.

Methadone reduces opioid use. It reduces overdose deaths. It reduces HIV transmission. It reduces criminal activity. A 2021 meta-analysis in The Lancet Psychiatry covering 196 studies and 32 countries found that methadone was the most effective pharmacological treatment for opioid use disorder across virtually every outcome measure studied. Among patients with severe dependence, it outperforms buprenorphine by a meaningful margin, particularly in retention — keeping people in treatment long enough to recover.

Dr. Joshua Sharfstein, former FDA principal deputy commissioner and current vice dean at Johns Hopkins Bloomberg School of Public Health, has written that the regulatory restriction on methadone is “one of the most consequential medical policy failures in American history — not because of what we did, but because of what we refused to allow.” He noted, in a 2024 analysis for Health Affairs, that the United States is one of the few high-income countries where methadone cannot be prescribed through ordinary medical practice.

France. Germany. Canada. Australia. Portugal. In each of these countries, a doctor can call in a methadone prescription to a pharmacy, just as they can for an opioid painkiller or an antidepressant. In the United States, the same doctor — board-certified in addiction medicine, with years of clinical experience — cannot.

The argument against this reform usually lands on diversion: the fear that methadone prescribed through pharmacies will be sold or shared illegally. This concern is not baseless. Methadone does appear in overdose statistics, most often in cases involving people who obtained it outside of treatment — a reason for careful monitoring. But the evidence from countries that allow pharmacy-based dispensing does not support the catastrophizing. Canada expanded methadone prescribing through standard pharmacies in the 1990s. Diversion increased modestly in the short term. Mortality fell substantially over the long term. The trade-off, studied with real data, looks very different from the trade-off imagined in political debate.

And there is the other side of the ledger — the one rarely cited in warnings about diversion. Every year, in every state, people with opioid use disorder who could be stable on methadone are instead cycling through detox, relapsing, and dying, because the clinic that could prescribe it to them requires attendance at hours they cannot keep, in a location they cannot reach, on a schedule that cannot coexist with the job or the children or the life that sobriety is supposed to return to them.

The Geography of Who Gets to Stay Alive

In Arizona — where Rize Recovery is building a treatment navigation platform — the stakes of this argument are not abstract. The state ranks 49th out of 51 jurisdictions for behavioral health access. Fewer than 1 in 20 Arizonans with opioid use disorder receive any medication-based treatment. That number is not a mystery or an accident. It is the predictable outcome of a policy architecture that restricts the most effective treatment to a small number of urban clinics.

Arizona has 2,664 recorded overdose deaths in 2022 — 14 percent above the national average. More than five Arizonans died from opioid overdoses every day that year. The 2026 CDC preliminary data showing a 13.2% national decline in overdose deaths — to approximately 69,147 for the 12 months ending January 2026 — is real, meaningful, and not what’s happening in Arizona. The state has trended in the wrong direction while the national picture improves.

Maricopa County has deployed $3.97 million in opioid settlement funds specifically to expand medication-assisted treatment access in county jails. That is good and necessary work. It is also evidence that the people most likely to touch the treatment system — those cycling through incarceration — are doing so partly because community-based treatment was unavailable or inaccessible when it might have diverted them.

Maricopa County has deployed $3.97 million in opioid settlement funds specifically to expand medication-assisted treatment access in county jails.

The Markey bill, if it passed, would not solve this instantly. Pharmacies would still need to stock methadone. Physicians would still need training in addiction medicine — and the shortage of addiction medicine specialists is significant, though real-world expansion of prescribing access consistently generates more trained prescribers over time, as buprenorphine’s history showed. Rural Arizona would still not have adequate providers overnight.

But it would create the possibility. It would allow a clinical relationship — a doctor who knows their patient, who has built trust, who has watched stability take hold over months — to evolve naturally into a treatment plan that does not require that patient to drive 94 miles round-trip on a Tuesday morning to prove they deserve to stay sober.

The Bill That Keeps Not Passing

The Modernizing Opioid Treatment Access Act was first introduced in 2023. It passed the Senate HELP Committee with bipartisan support. It went to the House and stalled — not because it was voted down, but because it was not voted on. Pharmaceutical advocates worried about competition. Some treatment center operators, whose business models depend on daily clinic attendance, lobbied against it. Political attention shifted.

The bill has now been reintroduced in a Congress where the political winds around drug policy are, to put it gently, complicated. The Trump administration’s 2026 National Drug Control Strategy emphasizes supply elimination and faith-based treatment — a framing that is less hostile to medication-based care than the administration’s rhetoric sometimes suggests, but also less urgently committed to it. SAMHSA, simultaneously, has been restricting harm reduction funding and facing questions about the durability of its support for MOUD programs under new leadership.

Sen. Markey and his colleagues are introducing this legislation into that environment, and the honest answer about its prospects is that they are uncertain. The evidence base is overwhelming. The political infrastructure to move the bill is not yet assembled.

What is assembled — and growing — is the clinical consensus. The American Society of Addiction Medicine. The American Academy of Addiction Psychiatry. The National Association of Drug Court Professionals. The American Medical Association. All of them support pharmacy-based methadone prescribing. The literature supports it. The international evidence supports it. The people who cannot get to the clinic, who are dying in counties with no OTP within a reasonable distance, support it with their absence from the treatment system and their presence in the overdose statistics.

Dana, for her part, is not waiting for Congress. She is still making the drive on Tuesday mornings. Eighteen months stable. Still alive.

“I try not to be angry,” she said. “But I have days where I think about what it would mean to just pick it up at Walgreens. I think about it every Tuesday.”

The bill has been introduced. The distance it must travel — through a Congress that has failed it once, in a political moment defined by ambivalence toward the policies that keep people alive — is longer than 94 miles. But it has a number now, and a sponsor, and the evidence has not changed. The next question is whether anyone is listening.